Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co ElifiledCriticalLilly Co Eli
Priority to DO2004000972ApriorityCriticalpatent/DOP2004000972A/en
Publication of DOP2004000972ApublicationCriticalpatent/DOP2004000972A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invencion proporciona un 7-cloro-6-(2,2,2-trifluoretilamino)2,3,4,5-tetrahidro-1H-benzo[d]azepina de formula I: o una sal del mismo farmacéuticamente aceptable, y su use como agonista selectivo de 5-HT2c para el tratamiento de trastornos asociados con los receptores 5-HT2c, incluyendo obesidad, trastorno obsesivo/compulsivo, ansiedad y depresion.The present invention provides a 7-chloro-6- (2,2,2-trifluoroethylamino) 2,3,4,5-tetrahydro-1H-benzo [d] azepine of formula I: or a pharmaceutically acceptable salt thereof, and its use as a selective 5-HT2c agonist for the treatment of disorders associated with 5-HT2c receptors, including obesity, obsessive / compulsive disorder, anxiety and depression.
DO2004000972A2004-08-092004-08-09
6- (2,2,2-TRIFLUOROETHYLAMINE) -7-CHLORINE-2,3,4,5-TETRAHYDR 1H-BENZO [D] AZEPIN AS A 5-HT2C RECEPTOR AGONIST
DOP2004000972A
(en)
Compounds derived from benzoyl-piperidine, 5ht2 / d3 receptor modulators; pharmaceutical composition that includes them; and their use in the treatment and / or prevention of delsnc pathologies, such as psychosis, schizophrenia, depression, anxiety, drug addiction and cognitive problems.